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ABSTRACT: Isoprenoid quinones are bioactive molecules that include an isoprenoid chain and a quinone head. They are tradition-
ally found to be involved in primary metabolism, where they act as electron transporters, but specialized isoprenoid quinones are also 
produced by all domains of life. Here, we report the engineering of a baker’s yeast strain, Saccharomyces cerevisiae EPYFA3, for 
the production of isoprenoid quinones. Our yeast strain was developed through overexpression of the shikimate pathway in a well-
established recipient strain (S. cerevisiae EPY300) where the mevalonate pathway is overexpressed. As a proof of concept, our new 
host strain was used to overproduce the endogenous isoprenoid quinone coenzyme Q6, resulting in a nearly three-fold production 
increase. EPYFA3 represents a valuable platform for the heterologous production of high value isoprenoid quinones. EPYFA3 will 
also facilitate the elucidation of isoprenoid quinone biosynthetic pathways. 
KEYWORDS: isoprenoid quinones, yeast, coenzyme Q6, shikimate pathway, specialized metabolites 
Isoprenoid quinones (IQs) are biologically active metabolites 
that are made of a hydrophobic isoprenoid tail and a polar qui-
none head.1 Traditionally, IQs have been found to act as elec-
tron transporters in respiratory and photosynthetic electron 
transport chains.2 In this context, the isoprenoid moiety allows 
IQs to be anchored to phospholipid bilayer membranes, 
whereas the polar head enables their interaction with proteins. 
Naphthoquinones (menaquinone and phylloquinone) contain a 
naphthalene-related quinone head, whereas benzoquinones 
(ubiquinone and plastoquinone) include a benzene-related qui-
none ring. IQs have mixed biosynthetic origins. Their isopre-
noid chain comes from isopentenyl pyrophosphate (IPP) and di-
methylallyl pyrophosphate (DMAPP).3 The quinone head can 
come from different sources, in particular from the O-suc-
cinylbenzoate pathway via chorismate or from the shikimate 
pathway via chorismate, tyrosine, or phenylalanine.2,4 Special-
ized IQs often include a polyketide head group, as commonly 
seen for fungal meroterpenoids.5 Ubiquinone-10 (coenzyme 
Q10),1 phylloquinone (vitamin K1)6 and α-tocopherol quinone 
(vitamin E quinone)7 are examples of widespread IQs (Figure 
1). Species-specific IQs, which are generally regarded as 
specialized metabolites, include the antitumor furaquinocin A,8 
the antiviral 4-hydroxypleurogrisein,9 the antioxidant naphter-
pins10 and the antitumor antibiotics BE-4064411 and shikonin 
(Figure 1).12,13  
The biosynthetic pathways to ubiquitous IQs have been 
investigated extensively, although a complete picture is still 
lacking for compounds such as coenzyme Q.14 The biosyn-
thesis of specialized IQs is often directed by cryptic meta-
bolic pathways. Their elucidation requires the use of inter-
disciplinary approaches, such as total synthesis and reconsti-
tution of in vitro reactions with recombinant biosynthetic en-
zymes, as shown for instance by Murray et al.10 for the bio-
synthesis of naphterpins and marinones. To increase IQs 
production and to facilitate the elucidation of their cryptic 
biosynthetic routes, a suitable biological platform providing 
ample precursor supply is needed.  
Here we report the engineering of a Saccharomyces cere-
visiae (baker’s yeast) strain that overproduces the building 




















































As a proof of concept, we used our strain to improve the 
production of coenzyme Q6. S. cerevisiae has been metabol-
ically engineered in the past to overproduce isoprenoids.15 
Notably, the Keasling lab has engineered the mevalonate 
pathway in yeast, in order to provide increased amounts of 
IPP and DMAPP for the assembly of various downstream 
products, such as the antimalarial drug precursor artemisinic 
acid,16 the biofuel precursor bisabolene,17 as well as natural 
and unnatural cannabinoids.18 Strain S. cerevisiae EPY300 
(Supporting Table S1) has been used to produce terpenoids, 
such as artemisinic acid16 and costunolide,19 in high 
amounts. 
EPY300 includes two copies of a truncated, soluble vari-
ant of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 
(tHMGR), as well as an additional copy of the farnesyl-py-
rophosphate (FPP) synthase gene ERG20, a copy of the 
semi-dominant allele upc2-1 for upregulation of genes in-
volved in the biosynthesis of sterols, and a methionine in-
ducible downregulation mechanism for the control of ERG9, 
which codes for squalene synthase (Scheme 1). Paradise et 
al.20 showed that in the presence of 1 mM methionine the 
vast majority of the isoprenoid flux in S. cerevisiae EPY213 
was diverted away from squalene and ergosterol production 
to yield amorphadiene. In EPY300 (which compared to 
EPY213 lacks the amorphadiene synthase-containing plas-
mid pRS425ADS and contains an additional chromosomal 
copy of tHMGR and ERG20 respectively) the majority of the 
isoprenoid flux would similarly be expected to be available 
to assemble the isoprenoid tail of coenzyme Q6 upon induc-
tion with methionine in a medium that contains either pure 
galactose or a mixed carbon source glucose/galactose.	 
In the present work, we acquired S. cerevisiae EPY300 
from the Keasling lab and engineered it further to overex-
press the shikimate pathway. The gene aroL codes for the 
shikimate kinase II in Escherichia coli,21 and its overexpres-
sion in S. cerevisiae has been shown to improve production 
of the shikimate pathway-derived p-coumaric acid.22 GCN4 
codes for a leucine zipper transcriptional activator (Gcn4p) 
in yeast, which is induced under amino acid starvation, and 
in turn triggers the upregulation of biosynthetic genes in-
volved in the production of most amino acids.23 The targets 
of Gcn4p include genes ARO1, ARO2, ARO3 and ARO4, 
which in yeast code for the enzymes that catalyze the seven 
steps of the shikimate pathway leading to chorismate. 
Chorismate can then be used for downstream processes, such 
as the biosynthesis of aromatic amino acids and that of the 
head group of IQs via 4-hydroxyphenylpyruvate (4-HPP). 
Genes ARO8 and ARO9, encoding aromatic aminotransfer-
ase I and II, respectively, are also among the targets of 
Gcn4p. Aro8p and Aro9p catalyze the conversion of 4-HPP 
into tyrosine and the reverse deamination reaction.24 Their 
upregulation can therefore provide additional 4-HPP, start-
ing from the tyrosine present in the culturing medium, that 
can be used to make the quinone head of IQs. Gcn4p also 
targets vitamin-cofactor biosynthetic genes, such as those 
that code for the enzymes responsible for the biosynthesis of 
NAD+, FAD and coenzyme-A, as well as for the biosynthe-
sis of tryptophan, a precursor of nicotinamide, which in turn 
is a component of NAD+ and NADP+.25 Therefore, overex-
pression of GCN4 can also lead to increased amounts of the 
cofactors that are required by secondary metabolite biosyn-
thetic enzymes, including those oxidoreductases that cata-
lyze the assembly of IQs. Eukaryotic cytochrome P450 en-
zymes, such as CYP76B74 involved in the biosynthesis of 
the IQ shikonin,26 require the cofactor NADPH as a source 
of electrons, and some dehydrogenases use NAD+ or 
NADP+ as electron acceptors.  
In order to produce a yeast strain that would accumulate 
precursors to IQs in high amounts, we set out to overexpress 
the shikimate pathway in EPY300. To introduce the E. coli 
aroL and overexpress the endogenous GCN4, we assembled 
the multigene vector pFA011 using the MoClo Yeast 
Toolkit27 (see Experimental Methods in the Supporting In-
formation for details on plasmid assembly). The sequence of 
the shikimate kinase II gene aroL (NCBI Gene ID: 945031) 
was codon-optimized for expression in S. cerevisiae (Sup-
porting Table S2), whereas GCN4 (NCBI Gene ID: 856709) 
was amplified from the genomic DNA of S. cerevisiae 
EPY300. The strong constitutive promoters pTEF1 and 
pTEF2 were placed upstream of aroL and GCN4, respec-
tively, as they are known to drive steady gene expression in 
media with different carbon sources.28 Upon linearization 
with NotI, pFA011 was introduced into S. cerevisiae 
EPY300 via the LiAc/single-stranded carrier DNA/PEG 













































Figure 1. Examples of isoprenoid quinones. 
 3 
Correct integration of linearized pFA011 in the LEU2 lo-
cus was verified through PCR amplification of the LEU2 5’ 
region (Supporting Figure S3a), as well as of the LEU2 3’ 
region (Supporting Figure S3b).  
In order to confirm that the target genes of interest were 
upregulated by the transcriptional activator Gcn4p in 
EPYFA3, we performed RT-qPCR analysis, targeting the ar-
omatic amino acid biosynthetic genes ARO1, ARO2, ARO3, 
ARO4, ARO8 and ARO9. The expression of GCN4 itself was 
also evaluated in EPYFA3 and compared to that of the 
GCN4 single copy-containing strain EPY300. The expres-
sion of GCN4 was confirmed to be higher in EPYFA3 than 
in EPY300 by almost a five-fold (Figure 2), due to the intro-
duction of a second copy of GCN4 under control of the 
strong constitutive pTEF2 promoter in EPYFA3. Upregula-
tion of ARO1, ARO2, ARO3, ARO4, ARO8 and ARO9 was 
confirmed upon overexpression of GCN4, in accordance 
with what described by Natarajan et al.,23 with values rang-
ing from a three- to a 22-fold increase in EPYFA3 compared 
to EPY300 (Figure 2). 
Next, we tested the ability of S. cerevisiae EPYFA3 to be 
used as a host for the increased production of IQs. As a proof 
of concept, we decided to test for the overproduction of 
ubiquinone-6 (coenzyme Q6), since this is the yeast endoge-
nous benzoquinone and is assembled by condensing build-
ing blocks deriving from the mevalonate and the shikimate 
pathways (see the review of Stefely and Pagliarini14 for an 
extensive overview of coenzyme Q biosynthesis). The qui-
none head of coenzyme Q6 in yeast comes from either 4-hy-
droxybenzoic acid (4-HB) or 4-aminobenzoic acid 
(pABA).30 In turn, 4-HB comes from 4-HPP, which can ei-
ther be made de novo through the shikimate pathway (in-
volving Aro1p, Aro2p, Aro3p and Aro4p) or derive from the 
deamination of tyrosine (involving Aro8p and Aro9p), 
which is an ingredient of synthetic defined (SD) medium at 
76 mg/L. Conversely, the isoprenoid tail of coenzyme Q6 in 
yeast comes from the mevalonate pathway, presumably as a 
result of the condensation of IPP with the allylic pyrophos-
phates DMAPP, geranyl-pyrophosphate (GPP) or FPP.3  
To assess the ability to redirect building blocks towards a 
specific metabolite of interest in EPYFA3, we overex-
pressed the gene COQ2, which codes for the 4-HB poly-
prenyltransferase, a UbiA family prenyltransferase that cat-
alyzes the first committed reaction in the biosynthesis of co-
enzyme Q6.31 The sequence of gene COQ2 (NCBI Gene ID: 
855778) was optimized to remove a BsmBI site through the 
introduction of a synonymous substitution (G885A).
Scheme 1. Schematic representation of the engineered metabolism of S. cerevisiae EPYFA3. Genes from the mevalo-
nate pathway are grouped in the yellow panel (adapted from Ro et al.16); genes from the shikimate pathway are grouped 
in the purple panel. Overexpressed genes are highlighted in light blue; genes indirectly upregulated (from upc2-1 for 
the mevalonate pathway and from GCN4 for the shikimate pathway) are highlighted in orange. Repression of ERG9 
through the methionine-repressible promoter PMET3 is represented in grey. Usage of DMAPP, GPP or FPP by COQ1 is 
shown through dashed lines as it is unclear which of these allylic pyrophosphates is used in vivo to make HexPP. The 
first reaction in the biosynthetic pathway to coenzyme Q6, the condensation of HexPP and 4-HB catalyzed by COQ2, 
is also shown. HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A; IPP: isopentenyl pyrophosphate; DMAPP: di-
methylallyl pyrophosphate; GPP: geranyl pyrophosphate; FPP farnesyl pyrophosphate; HexPP: hexaprenyl pyrophos-
phate; 4-HB: 4-hydroxybenzoic acid; HHB: 3-hexaprenyl-4-hydroxybenzoic acid; HAB: 3-hexaprenyl-4-aminobenzoic 



































































We assembled an expression vector, pFA004, that con-
tained a copy of COQ2 under control of the strong constitu-
tive promoter pCCW12 (see Experimental Methods in the 
Supporting Information for details on plasmid assembly). 
Upon linearization with NotI, pFA004 was introduced into 
both S. cerevisiae EPY300 and EPYFA3 via the LiAc/sin-
gle-stranded carrier DNA/PEG method,29 producing strains 
EPYFA4 and EPYFA7 respectively. Correct integration of 
linearized pFA004 in the URA3 locus was verified through 
PCR amplification of the URA3 5’ region (Supporting Fig-
ure S3c), as well as of the URA3 3’ region (Supporting Fig-
ure S3d). Control strains with matching auxotrophy require-
ments to EPYFA3, EPYFA4 and EPYFA7 were also gener-
ated through the integration in EPY300 of empty vectors 
pFA010 (giving strain EPYDA1), pYTK09627 (giving strain 
EPYDA2) and both pFA010 and pYTK096 (giving strain 
EPYDA3). Correct integration of these vectors in the URA3 
and LEU2 loci was verified through PCR amplification 
(Supporting Figure S4a-d). 
We determined the amount of coenzyme Q6 accumulated 
in strains EPY300, EPYFA3, EPYFA4 and EPYFA7, as 
well as in control strains EPYDA1, EPYDA2 and EPYDA3. 
Most of the coenzyme Q6 produced by S. cerevisiae in syn-
thetic medium is known to originate from the pABA that is 
either acquired from the medium or synthesized endoge-
nously.30 To obtain a clear insight into the effect of the genetic 
modifications object of our study, we performed coenzyme Q6 
measurements from yeast cells grown in SD media lacking 
pABA. Folic acid, which is assembled using pABA and may 
therefore be depleted in its absence, was added to all cultures at 
a concentration of 20 µM. Lipids were extracted from pelleted 
cells using a modified protocol from Marbois et al.32 (see 
Experimental Methods in the Supporting Information). Co-
enzyme Q4 (Sigma-Aldrich) was used as an internal standard 
and added to all samples in a known amount (expected final 
concentration 5 pmol μL-1). Samples were analyzed through 
reversed-phase HPLC diode-array base-peak chromatogram 
obtained at 274 nm. Quantification was performed using a 
coenzyme Q6 (Sigma-Aldrich) external standard and a 
calibration curve, through the integration of the area under-
neath the UV peak corresponding to coenzyme Q6; the re-
covery of the internal standard coenzyme Q4 from the lipid 
extracts was determined through a calibration curve and 
used to adjust the measured amounts of coenzyme Q6 for the 
extraction efficiency. The identity of coenzyme Q6 in the 
yeast extracts was confirmed through mass spectrometry 
(Supporting Figure S5); other metabolites observed in the 
UV chromatograms could not be unambiguously assigned 
based on their m/z values. An increase in coenzyme Q6 pro-
duction could be observed upon overexpression of the shiki-
mate pathway in strain EPYFA3 (Figure 3), which accumu-
lated 49.4 (± 6.2) pmol mg-1 wet cell weight (WCW), com-
pared to EPYDA1, which produced 23.0 (± 10.3) pmol mg-
1 WCW. Similarly, increased production was detected when 
COQ2 was being overexpressed in EPYFA7, corresponding 
to 52.4 (± 8.2) pmol mg-1 WCW, compared to strain 
EPYFA4 where COQ2 was also overexpressed but the shi-
kimate pathway was not, which accumulated 30.1 (± 2.7) 
pmol mg-1 WCW. Interestingly, no significant difference 
could be observed between strains EPYFA3 and EPYFA7, 
suggesting that overexpression of the shikimate pathway 
was the main player in the increased production of coenzyme 
Q6 in this strain as opposed to overexpression of COQ2. 
It should be noted that methionine is used to downregulate 
the expression of the squalene synthase gene ERG9 but it is 
also consumed during coenzyme Q6 biosynthesis in S. cere-
visiae, as S-adenosylmethionine (SAM) is employed as a co-
factor by the O-methyltransferase Coq3p in the catalysis of 
two coenzyme Q6 biosynthetic steps.33 However, the amount 
of coenzyme Q6 produced by EPYFA7 corresponds to 70.71 
(± 6.44) nM. Therefore, only 141.42 (± 12.88) nM equiva-
lent of methionine is used for the production of coenzyme 
Q6 by the highest producing strain, meaning that ample me-
thionine is available to direct downregulation of ERG9 
through the methionine-repressible promoter PMET3 (Scheme 
1). 
The growth of the four yeast strains was monitored in the 
same conditions used to extract lipids, measuring the OD600 
at various timepoints (Supporting Figure S6). A significant 
difference in growth was observed only between EPYFA7 
and EPYDA3, with EPYFA7 showing a 15% (p<0.001; un-
paired two-tailed t test) higher OD600 at stationary phase (7-
day timepoint) than EPYDA3, putatively due to an improved 
fitness upon accumulation of additional coenzyme Q6. 
Noteworthily, since S. cerevisiae EPYFA3 is a derivative 
of BY4742, it harbors unused auxotrophic markers that can 
be employed to introduce other expression vectors. Loci 
LYS2 (mutated to lys2Δ0), URA3 (mutated to ura3Δ0) and 
HO can be used for the chromosomal integration of up to 
three plasmids. LYS2, URA3, as well as expression cassettes 
for resistance to antifungals, such as HygromycinR and 
KanMXR, can be used as selectable markers for the mainte-
nance of integrative and/or replicative plasmids. This will 
allow EPYFA3 to be used to reconstitute the biosynthesis of 
IQs, as well as that of any other compounds derived from the 
mevalonate and the shikimate metabolic pathways.  
Figure 2. RT-qPCR expression analysis. Relative transcript 
abundance of genes ARO1, ARO2, ARO3, ARO4, ARO8, 
ARO9 and GCN4 in S. cerevisiae EPYFA3. Actin (ACT1) was 
used as the reference gene, and the average Ct value of each 
target gene in S. cerevisiae EPY300 was used as the calibrator 
(the expression of each gene in S. cerevisiae EPYFA3 is 
shown relative to the expression of the same gene in S. cere-
visiae EPY300). Values and error bars reflect mean and stand-
























In conclusion, we have engineered a yeast strain that over-
expresses both the mevalonate and the shikimate pathways 
and can therefore be used to produce IQs in which the qui-
none ring derives from the shikimate pathway. Our approach 
involved the overexpression of the E. coli shikimate kinase 
II gene aroL and that of the transcriptional activator GCN4, 
which in turn led to the upregulation of shikimate pathway 
genes ARO1, ARO2, ARO3 and ARO4, as well as of ARO8 
and ARO9. Our strategy was similar to the one adopted by 
Ro et al.16, who achieved upregulation of mevalonate path-
way genes through the overexpression of the transcriptional 
activator upc2-1. Further improvement of our strain 
EPYFA3 may be achieved through a targeted overexpres-
sion of each shikimate pathway gene, similarly to what done 
by Westfall et al.34 for the mevalonate pathway. Multiple 
copies of aroL could be introduced, as the encoded enzyme 
has a high metabolic flux control.22 Galactose-inducible pro-
moters may be used to drive the overexpression of shikimate 
pathway genes (and COQ2), in order to coordinate their ex-
pression with that of mevalonate pathway genes. Addition-
ally, it should be noted that coenzyme Q6 measurements in 
this work were carried out in SD medium lacking pABA to 
appreciate the effects of the genetic modifications that targeted 
the ARO genes. Inclusion in the medium of pABA, which is the 
main precursor of the head group of coenzyme Q6 in S. cere-
visiae,30 is expected to lead to higher amounts of coenzyme Q6.  
We envisage that our strain will be particularly useful to 
express prenyltransferase enzymes and other IQ biosynthetic 
enzymes, which have recently gained attention as potential 
biocatalysts.35 It will also enable to support accumulation of 
metabolites in amounts sufficient for purification and 
structure determination. Therefore, it will be a valuable plat-
form to refactor and characterize the cryptic biosynthesis of 
specialized IQs for which a fast-growing heterologous host 
is needed.  
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